ESC Premium Access

Risk of qtc interval prolongation among cancer patients treated with tyrosine kinase inhibitors

Topic: Cardiotoxicity of Drugs

Congress Presentation

6 more presentations in this session

Research Network in Africa (RNA): quality assessment of antihypertensive generic drugs in 10 African countries

Speaker: Doctor D. Macquart de Terline (Paris, FR)


Clinical pharmacology of AZD9977, a novel, selective mineralocorticoid receptor (MR) modulator without K+-sparing properties

Speaker: Doctor A. Whittaker (Gothenburg, SE)


Impact on the prognosis of treatment administrated in the daily clinical practice to patients with myocardial infarction with non-obstructive coronary arteries.

Speaker: Doctor J. Lopez-Pais (Santiago de Compostela, ES)


Trends in indications and outcome in thrombolytic therapy: a retrospective single center study

Speaker: Doctor M. Engelen (Leuven, BE)


Cardioprotective anti inflammatory effects of empaglifozin in doxorubicin induced cardiotoxicity: the role of leukotriene B4 and interleukin 1

Speaker: Doctor N. Maurea (Naples, IT)


Access the full session

Cardiovascular pharmacotherapy

Speakers: Doctor D. Macquart de Terline, Doctor A. Whittaker, Doctor J. Lopez-Pais, Doctor M. Engelen, Doctor N. Maurea

About the event


ESC Congress 2019

31 August - 4 September 2019

Sessions Presentations

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb